Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
CEO Witty set to step aside at GSK |
||||||||||||||||||
Andrew Witty is giving up the CEO job at U.K. drug giant GlaxoSmithKline ($GSK), announcing this week he'll step aside in March 2017 following months of investor pressure on the company and rumors he'd be leaving. Witty took the job in 2008 and has worked to steer the pharma toward reliable, lower-margin products such as vaccines and consumer drugs and away from high-risk pharma. Investors started grumbling in 2014 when GSK was caught up in a bribery scandal in China and paid a $489 million fine as a result, but Advair's collapse really turned up the heat. The transition timeline will give GSK plenty of time to scout for replacement candidates, with market watchers pointing to GSK CFO Simon Dingemans and Novartis' ($NVS) pharma chief David Epstein as possibilities. "I believe this will be the right time for a new leader to take over," Witty said in a statement about his departure. "In making this decision it has been important to me that the board has the time to conduct a full and proper process." Story
|